Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension.
Silvio DaneseRemo PanaccioneMaria T AbreuDavid T RubinSubrata GhoshAxel DignassAnita AfzaliDouglas C WolfMichael V ChioreanSeverine VermeireAnjali JainLorna CharlesGarrett LawlorMark T OstermanHsiuanlin WuJames B CanavanAnn Katrin PetersenJean Frederic ColombelMiguel RegueiroPublished in: Journal of Crohn's & colitis (2023)
Among patients who achieved clinical response after 1 year of ozanimod treatment during True North, a high percentage sustained clinical and mucosal efficacy over 2 additional years in the OLE. No new safety signals were observed with long-term ozanimod use.